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'is study investigated the in vivo antileukemic activity of palladium nanoparticles (Pd@W.tea-NPs) mediated by white tea extract in
a murine model. 'e cell viability effect of Pd@W.tea-NPs, “blank” Pd nanoparticles, and white tea extract alone was determined in
murine leukemiaWEHI-3B cells and normalmouse fibroblasts (3T3 cells). Apoptotic and cell cycle arrest effects of Pd@W.tea-NPs in
WEHI-3B cells were evaluated.'e effects of Pd@W.tea-NPs administered orally to leukemic mice at 50 and 100mg/kg daily over 28
days were evaluated. Pd@W.tea-NPs reduced the viability ofWHEI-3B cells with IC50 7.55 μg/ml at 72 h. Blank Pd nanoparticles and
white tea extract alone had smaller effects onWHEI-3B viability and on normal fibroblasts. Pd@W.tea-NPs increased the proportion
of Annexin V-positive WHEI-3B cells and induced G2/M cell cycle arrest. Leukemic cells in the spleen were reduced by Pd@W.tea-
NPs with an increase in Bax/Bcl-2 and cytochrome-C protein and mRNA levels indicating the activation of the mitochondrial
apoptotic pathway.'ese effects replicated the effects of ATRA and were not observed using blank Pd nanoparticles. Pd@W.tea-NPs
afford therapeutic efficacy against leukemia likely to pivot on activation of the mitochondrial pathway of apoptotic signaling and
hence appear attractive potential candidates for development as a novel anticancer agent.
1. Introduction
A substantial proportion of 10 million new cancers reported
globally each year, and of those, 6 million annual cancer
deaths are due to leukemia [1]. It is estimated by the National
Cancer Institute that leukemia will account for 3.5% (over
60,000) of new cancers in the US population in 2019 and for
3.8% of all cancer deaths [2]. Conventional therapies such as
imatinib mesylate (Glivec), all-trans retinoic acid (ATRA),
arsenic trioxide (ATO), and doxorubicin (DOX) can be
highly effective, especially in newly diagnosed acute leuke-
mias. However, the chances of relapse, fatal side effects, and
development of multidrug resistance are high [3]. 'us, less
toxic and more target-specific therapies are desirable. In this
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regard, dependable, environmentally benign processes for
the synthesis of nanoscale materials that simultaneously
confer additional beneficial properties through the incor-
poration of natural molecules, such as antioxidants, from the
reaction mixture is a promising development in nano-
medicine for the treatment of cancer, including leukemia
[4–6]. 'e use of bioresources, including plant products, in
the synthesis of metal nanoparticles shows promise in this
regard, as well as in providing a viable and cost-effective
approach with minimal environmental impact for a wide
range of other potential applications, including in optics and
biomedicine. 'e activities of natural chemical reductants in
plants with ethnobotanical relevance that also have reported
antimicrobial, anticancer, antioxidant, and/or anti-inflam-
matory activities have been harnessed to synthesize palla-
dium nanoparticles (Pd-NPs). 'ese include cinnamon
(Cinnamomum camphora) leaf [7], black tea (C. sinensis) leaf
[8], fenugreek (Trigonella foenum-graecum) [9], gum ghatti
(Anogeissus latifolia) [10], Chlorella vulgaris [11], white tea
(C. sinensis) [12, 13] citrus fruit (Cymbopogon citratus) [14],
and barberry fruit [15].
Tea, which belongs to the family 'eaceae, is mainly
planted in China, India, and, to a lesser extent, in tropical
regions. Time of harvesting and processing is generally
species-specific and confers different qualities and proper-
ties. White tea (Camellia sinensis), which is harvested before
the leaves open fully, when the young buds are still covered
by fine white hairs [12], has been used as a traditional
treatment for various diseases including diabetes, inflam-
mation, obesity, aging, osteoporosis, and cancer [16]. It is
well-known for its high content of polyphenols, particularly
catechin [13, 16, 17]. 'ese chemicals are known to have
wide spectrum of biological effects such as antioxidant,
anticancerous, antiviral, and antifungal effects [18, 19].
Previously, we reported the first synthesis of a Pd-NP
composite using white tea extract. 'e in vitro antioxidant,
antibacterial, and antiproliferative activities toward the
human leukemia (MOLT-4) cell line were enhanced com-
pared with normal human fibroblasts [7]. To our knowledge,
the effect of white tea extract-derived Pd-NPs (Pd@W.tea-
NPs) on leukemic cells in vivo has not been reported. 'us,
we investigated the antileukemic effects of Pd@W.tea-NPs in
vivo using a murine model of acute myelocytic leukemia. We
also confirmed that our previous finding that these nano-
particles have activity in vitro (in human leukemia cells) that
is enhanced compared with normal human fibroblasts ap-
plies also in murine leukemia cells (WEHI-3B) compared
with normal murine fibroblasts.
2. Materials and Methods
2.1. Preparation and Characterization of Palladium
Nanoparticles. Palladium nanoparticles were prepared and
characterized as described previously [7]. In brief, 50ml of
freshly prepared clear extract of white tea was dispersed in a
flask containing 50ml of 1mM PdCl2 solution at 40°C with
constant stirring. Over ∼30min, the colour of the reaction
contents gradually changed from transparent yellow to dark
brown, indicating successful formation of Pd-NPs. 'e
reaction was allowed to continue for 2 h. 'e product was
then concentrated by centrifugation at 6000 rpm for 10min.
Finally, the sample was oven-dried (60°C), until it had the
appearance of a fine powder, and then stored in a clean glass
container. “Blank” palladium nanoparticles were prepared in
the absence of white tea extract. Pd@W.tea-NPs were
characterized using UV-visible spectrophotometry (Lambda
25-Perkin-Elmer, Waltham, MA, USA), Fourier-transform
infrared (FTIR) spectrometry (Perkin-Elmer 1725X), X-ray
diffraction (XRD-6000; Shimadzu), transmission electron
microscopy (Hitachi H-7650, Tokyo, Japan), and scanning
electron microscopy (Philips XL-30, Germany).
2.2. Measurement of Anticancer Activity In Vitro
2.2.1. Cell Lines and Culture Conditions. Murine myelocytic
leukemia (WEHI-3B) and murine fibroblast (3T3) cell lines
were purchased from the American Type Culture Collection
(ATCC) (Manassas, VA, USA). Cells were maintained in
complete RPMI-1640 medium supplemented with 10% FBS
and 1% antibiotic-antimycotic in 75 cm2 culture flasks (TPP,
Trasadingen, Switzerland) at 37°C and 5% CO2 in a hu-
midified incubator (Binder, Tuttlingen, Germany).
2.2.2. Cytotoxicity Assay. 'e cytotoxic effect of Pd@W.tea-
NPs, blank Pd-NPs, and white tea extract alone onWEHI-3B
and 3T3 cells was measured using MTT assay. Cells were
seeded at a density of 1× 104 cells per well in 1ml RPMI-
1640 or DMEM medium, respectively, in 96-well plates and
exposed to test agents 24 h after seeding. 'en, they were
kept for 24, 48, or 72 h in a CO2 incubator. MTT (5mg/ml in
PBS) was then added, and cells were incubated for further 3 h
at 37°C. DMSO was added to reduce tetrazole to formazan,
and concentration was measured at 570 nm (Bio-Rad, Model
680). IC50 was calculated by comparison with unexposed
cells.
2.2.3. Detection of Apoptotic Cells Using FITC-Annexin V
and Propidium Iodide. WEHI-3B cells (∼1× 106) were
seeded in a 25 cm2 flask and then treated with Pd@W.tea-
NPs at IC50 for 24, 48, or 72 h. Cells grown in culture
medium without Pd@W.tea-NPs were used as controls at
each time point. Cells were then stained with Annexin V and
propidium iodide (PI) using the apoptosis detection kit (BD
Biosciences, San Jose, CA, USA) according to the manu-
facturer’s instructions. Annexin V-FITC and PI binding
were analyzed immediately by flow cytometry (FACS Cal-
ibur, BD Biosciences, San Jose, CA, USA). Cell Quest
software was used for quadrant analysis.
2.2.4. Cell Cycle Assay. Cell seeding and treatment for
measurement of the cell cycle was as described for mea-
surement of apoptosis. Cells were harvested, fixed, and
permeabilized with 70% ethanol at −20°C for at least 72 h,
washed and resuspended in 0.5ml PBS containing propi-
dium iodide (1mg/ml) and RNases (0.5mg/ml), and then
incubated for at least 30min at 4°C in the dark. Finally, the
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DNA content was quantified by flow cytometry (FACS
Calibur (BD Biosciences, San Jose, CA, USA) using BD
FACS Diva software for data analysis as reported previously
[20].
2.3. Measurement of Anticancer Activity In Vivo
2.3.1. Animals. 'irty-six male BALB/c mice, 6–8 weeks old,
with an average body weight of 20–25 g, were supplied by the
Animal House, Faculty of Veterinary Medicine, Universiti
Putra Malaysia (UPM). 'e animals were kept in 12 h light
and dark cycles at a controlled temperature of 25± 2°C and
fed regularly with mouse chow. Mice were housed for a week
under these conditions to allow acclimatization before
treatment. 'e study was approved by the Animal Care and
Use Committee (ACUC), Faculty of Veterinary Medicine,
Universiti Putra Malaysia (ref.: UPM/IACUC/AUP-R055/
2017).
2.3.2. Animal Grouping, Cancer Induction, and Treatment.
Mice were allotted into 6 groups (n� 6), namely, I: negative
control, II: cancer control, III: treatment 1, IV: treatment 2,
V: blank Pd-NP, and VI: positive control. Leukemia allo-
grafts were then established by injecting 1× 106 WEHI-
3B cells suspended in 300 μl ice-cold PBS intraperitoneally
into the abdomen of each mouse except those in group
I. Mice were tested daily for the development of leukemia by
the detection of leukemic cells in a tail vein blood smear
using Wright stain. Once leukemia was established, several
days after the injection of WEHI-3B cells, treatments were
administered daily for 4 weeks by oral dosage of 300 μl after
12 h without food using a syringe and ball-tip stainless-steel
needle. Group II received saline only; group III received Pd@
W.tea-NPs at 50mg/kg; group IV received Pd@W.tea-NPs
at 100mg/kg; group V received Blank Pd-NPs at 100mg/kg;
and group VI received ATRA (5mg/kg). Group I received no
oral dose. 'e condition of animals was monitored daily. At
the end of the study, animals were anesthetized by intra-
peritoneal injection of ketamine (83mg/g) and xylazine
(13mg/g) and then sacrificed. 'e spleen was collected for
macroscopic and microscopic analysis.
2.3.3. Serum Biochemistry. Blood samples were collected by
heart puncture. Serum was collected and analyzed imme-
diately using standard diagnostic kits (Roche) in an auto-
matic biochemistry analyser (Hitachi 902, Japan).
2.3.4. Measurement of Spleen. 'e size of the spleen collected
from each animal was measured immediately using a caliper,
and then, the spleens were weighed and photographed.
2.3.5. Histopathological Examination of the Spleen.
Spleens were washed with normal saline, fixed in 10%
formalin, passed through ascending concentrations of eth-
anol (50, 70, 90, and 100%), embedded in paraffin wax, and
then sectioned. Before staining, sections were cleared of wax
in 2 changes of xylene for 3min each, hydrated by passing
through descending concentrations of ethanol (2 changes
each at 100, then 70%), and rinsed with water for 3min.
Sections were then stained with hematoxylin and eosin
(H&E). After staining, sections were dehydrated in as-
cending concentrations of ethanol (2 changes each for 3min
at 70, then 100%) and then cleared in 2 changes of xylene for
3min each. Histopathological features, comprising vessel
congestion, red blood cell extravasation, hematoma, cell
necrosis, nuclear changes, and fibrosis, were scored in 4
sections from each mouse by a blinded observer, and the
spleens were graded as 0 (no distinguishable change); 1 (mild
change—up to 30%); 2 (moderate change—31–60%); and 3
(severe change—61–100%). Data were analyzed using the
Mann–Whitney test (SPSS 16.0), taking P< 0.05 as signif-
icant change.
2.3.6. Immunohistochemical Examination of the Spleen.
'e Dako Envision®+Dual Link System-HRP (DAB+) kit(Dako K4965, USA) was used, with a slight modification of
the protocol, to detect apoptotic cells in the spleen. Tissue
sections, prepared as above, were deparaffinized, rehydrated
with ascending concentrations of ethanol (100, 90, and 70%),
and washed in distilled water. Wax-enclosed sections were
then flooded with dual endogenous enzyme (Dako K4065,
USA) as a blocking agent and incubated for 10min. Sections
were then washed with citrate buffer solution (10mM, pH
6.0) (Sigma, USA), immersed in tris-buffered saline with
Tween-20 (TBST) for 3min, and then incubated with CD3
primary antibody (T-lymphocyte marker) (Abcam ab5690,
UK) or CD19 primary antibody (B-lymphocyte marker)
(Bioss bs0079R, USA) at 4°C overnight. After washing with
TBST, sections were incubated for 45min with labeled
polymer-HRP reagent (Dako K4065, USA) and then washed
again with TBST. DAB+ substrate-chromogen solution
(Dako K4065, USA) was then applied for 3min. Finally,
sections were counterstained with Myer’s hematoxylin,
mounted in DPX medium, and observed under a light
microscope at 40x magnification.
2.3.7. Western Blotting. Total protein was extracted from
splenic tissues using RIPA buffer (Sigma-Aldrich, USA)
supplemented with protease inhibitor cocktail (Sigma
Aldrich Co, LLC, USA). Samples of 20 μg were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and then transferred to PVDF membranes.
Membranes were probed using specific primary antibodies
against GAPDH (Abcam ab8245), Bcl-2 (Abcam ab59348),
Bax (Abcam ab32503), or cytochrome-C (Abcam ab13575)
at 4°C overnight. After washing 3 times (for 5min each) in
TBST, the ALP-conjugated goat anti-rabbit secondary an-
tibody (Bio-Rad ab20571 for anti-Bcl-2 and anti-Bax pri-
maries) or goat anti-mouse secondary antibody (Bio-Rad
170-6464 for anti-GAPDH anti-cytochrome-C primary) was
applied, and membranes were then incubated with NBT-
BCIP buffer for 15min in the dark. Protein bands were
visualized and captured using a Bio-Rad Gel Doc system and
quantified by densitometry using molecular imaging soft-
ware (ImageJ 148-JDK 6 software).
Evidence-Based Complementary and Alternative Medicine 3
2.3.8. RT-qPCR. Spleens were placed in RNAlater (Ambion,
USA) overnight at 4°C before beingminced and then stored in a
freezer at −80°C. Tissues were snap-frozen in liquid nitrogen
and crushed to a powder before total RNA was extracted using
the Qiagen RNAeasy Mini Kit (Qiagen, Germany) and quan-
tified using a nanospectrophotometer (Beckton Coulter, USA).
Adequate purity was confirmed based on A260/A280 ratios of
1.8–2.1. Reverse transcription to cDNA was achieved using the
Maxima First Strand cDNA synthesis kit ('ermo Scientific,
USA). Quantity of Bax, Bcl-2, cytochrome-C, and GAPDH
mRNA was measured using SYBR Select Master Mix (Life
Technologies, USA) in an Eco Illumina instrument (Illumina,
USA) using thermal cycling parameters (optimised for each
primer pair) of 95°C for 10min and then 40 cycles of 95°C for
15 s and 55–60°C for 15–30 s. Quantity of Bax, Bcl-2, or cy-
tochrome-CmRNAwas expressed in relation to GAPDHusing
standard curves for each mRNA and a delta-Ct relative
quantification model with PCR efficiency correction using Eco
Study software (Illumina,USA).'e target cDNAwas amplified
using the following primers: Bcl-2-forward 5′-CCA-
GACTCATTCAACCAGACA-3′ and reverse 5′-GATGACT-
GAGTACCTGAACCG-3′; Bax-forward 5′-TTTGCTACAG
GGTTTCAT-3′ and reverse 5′-CTCCATATTGCTGTCCAG-
3′; cyt-C forward 5′-GTCTTATGCTTGCCTCCCTT-3′ and
reverse 5′-CGTCTGTCTTCGAGTCCGA-3′; and GAPDH
forward 5′-CGGGACCTAATGAAACTCCA -3′ and reverse
5′-AATCTCCACTTTGCCACTGC-3′.
2.4. Statistical Analysis. All data points determined by
western blotting or RT-qPCR were measured in at least
triplicate and expressed as mean± SEM. Statistical signifi-
cance was evaluated by one-way ANOVA (using Origin 6.1,
Northampton, MA) followed by Tukey’s B-test, considering
P< 0.05 as significant.
3. Results
3.1. CytotoxicActivity. Pd@W.tea-NPs had a cytotoxic effect
on WEHI-3B cells that was dose-dependent and observed as
early as 24 h after exposure. Cytotoxicity increased with time
up to at least 72 h, at which point cell viability was reduced to
20% (Figure 1(a)). IC50 values at 24, 48, and 72 h were 16.77,
10.25, and 7.55 μg/ml, respectively. In contrast, viability of
normal mouse fibroblast (3T3) cells was reduced only to 60%
by the same maximal exposure (Figure 1(b)). Compared
with Pd@W.tea-NPs, both “blank” Pd-NPs and white tea
extract had a smaller effect on the viability ofWEHI-3B cells,
whereas Pd@W.tea-NPs reduced viability to as low as 20%
over concentrations increasing to 100 μg/ml, and the same
concentration range of the blank NPs or white tea extract
achieved only a 50% reduction (Figures 1(c) and 1(d)). 'us,
we confirmed that, as observed previously in humanMOLT-
4 leukemic cells [6], Pd@W.tea-NPs weremore effective than
white tea extract in reducing the viability of mouse WEHI-
3B leukemic cells and also had a differential effect on the
leukemic cell line compared with normal fibroblasts.We also
demonstrated that Pd@W.tea-NPs had a greater antileu-
kemic action than “blank” NPs in this in vitro model.
3.2. Apoptosis Analysis. Flow cytometric analysis revealed
that treatment of WEHI-3B cells with Pd@W.tea-NPs in-
creased the percentage of Annexin V-FITC-positive cells,
indicating in increase in both early and late apoptosis. 'is
effect was dose-dependent, and most marked after longer
exposures (Figure 2). At the IC50 of 7.55 μg/ml for 72 h
exposure, there was an obvious and significant (P< 0.05)
increase in the percentage of Annexin V-FITC-positive
apoptotic WEHI-3B cells compared with untreated control
cells (Figure 2).
'e distribution of WEHI-3B cells across the phases of
cell cycle was measured by flow cytometry after treatment
with Pd@W.tea-NPs at 72 h IC50 of 7.55 μg/ml at 24, 48, and
72 h (Figure 3). 'e results showed that Pd@W.tea-NPs
induced G2/M phase arrest (Figure 3(d)). 'e number of
cells in the G2/M phase was increased significantly (P< 0.05)
at 24 and 48 h. At 48 h, there was also a significant (P< 0.05)
increase in the sub-G0/G1 population of cells exposed to
Pd@W.tea-NPs.
3.3. Biochemical Indicators of Renal and Liver Function.
Both serum liver enzymes and renal function parameters
were significantly (P< 0.05) increased in both the leukemia
control and blank NPs groups compared with negative
control mice. In contrast, all parameters in the Pd@W.tea-
NPs- and ATRA-treated groups were significantly decreased
(P< 0.05) compared with the induced leukemia control
group (Table 1).
ATRA treatment and also treatment with NPs at the
higher concentration for some parameters restored these
measures to negative control levels, demonstrating that the
pathological features the mouse model of leukemia were not
simple due to over toxicity.
3.4. Morphological Characterization of the Spleen.
Treatment of mice in which leukemia was induced by in-
traperitoneal injection of WEHI-3B (mouse leukemic) cells
with Pd@W.tea-NPs reduced the size of the spleen, com-
mensurate with an anticancer effect, and was also observed
for ATRA (positive control). Length of the spleen was re-
duced significantly (P< 0.05) after treatment with Pd@
W.tea-NPs at both the higher and lower doses tested. In
contrast, blank NPs did not reduce spleen length (Table 2).
'e weight of the spleen in the groups treated with Pd@
W.tea-NPs was also reduced significantly (P< 0.05) at both
the higher and lower doses. In contrast, blank NPs did not
reduce spleen weight (Table 2).
3.5. Microscopic Characterization of the Spleen. Neoplastic
cells observed in tissues stained with H&E, characterized by
large irregular nuclei with clumped chromatin, clear and
light eosinophilic cytoplasm, and irregularity in size and
shape, were observed in the red and white pulp in sections of
spleen taken from animals in which leukemia was induced
and led to the disappearance of sinusoids (Figure 4, compare
panels A and B). 'ese histopathological features were re-
duced in animals treated with both the lower and higher
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Figure 1: Effects of increasing concentrations of Pd@W.tea-NPs (a, b), blank NPs (c), or white tea extract (d) on the viability of murine
myelocytic leukemia cells (WEHI-3B; (a, c, d)) or normal mouse fibroblasts (3T3; b) measured using the MTT assay. 'e values were
expressed as a percentage in relation to the negative control group. Cells were treated for 24, 48, or 72 h as indicated. NPs: nanoparticles.
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doses of Pd@W.tea-NPs (Figures 4(c) and 4(d)), as well as by
ATRA (Figure 5(f)). In contrast, blank NPs did not affect the
neoplastic appearance of the tissue (Figure 4(e)). 'e
percentage of cells scored as neoplastic differed significantly
(P< 0.05) between sections of spleen from healthy control
mice and mice with induced leukemia that did not receive





























































































Figure 2: Induction of apoptosis in murine myelocytic leukemia (WEHI-3B) cells by Pd@W.tea-NPs after exposure for (a) 24, (b) 48, or (c)
72 h at IC50 (16.77 μg/ml). Apoptosis was detected by staining with Annexin V-FITC followed by flow cytometry. Panels A1, B1, and C1 show
untreated (control) cells, while panels A2, B2, and C2 show cells treated with Pd@W.tea-NPs. (d) Quantitative analysis of the flow cytometer
data. Values are mean± SD for three different independent experiments. ∗P< 0.05 by one-way ANOVA followed by Tukey’s B-test.
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NPs and between healthy control mice and mice with in-
duced leukemia treated with blank NPs. 'e percentage of
neoplastic cells also differed significantly (P< 0.05) between
mice with induced leukemia that did not receive NPs and
mice treated with either dose of Pd@W.tea-NPs or with
ATRA (Table 3). Tand B lymphocytes observed in spleen by
immunohistochemical detection of the CD3 T-cell marker
[21] and the CD19 B-cell marker18 showed significant
differences between treatment groups that were completely
consistent with the differences revealed by H&E staining,
with CD3-positive cells (T cells) being in the white pulp
(Figure 5) and CD19-positive cells (B cells) being in the red
pulp (Figure 6).
3.6. Determination of Apoptosis Biomarkers. Protein deter-
mination by western blot (Figure 7) andmRNA by RT-qPCR
(Table 4) has revealed a significant increase in Bcl-2 and
cleaved cytochrome-C and a significant reduction in Bax
(consistent with stimulation of the caspase-induced pathway
of apoptosis) in spleen from the groups treated with Pd@
W.tea-NPs at both doses tested, as well as in the group
treated with ATRA (positive control), compared with the
untreated, leukemic group. In contrast, the group treated
with blank NPs showed no differences from the untreated
leukemic group.
4. Discussion
Over recent years, a plethora of plant part crude extracts and
active compounds have been studied for their potential to
generate inorganic NPs, and among them, Camellia sinensis
(white tea) is the significant one [22]. Extract from the
unfermented young tea leaves or unopened buds acts as an
efficient reducing and capping agent to generate palladium





























Figure 3: Analysis by flow cytometry of WEHI-3B cells treated with Pd@W.tea-NPs at 7.55 μg/ml (IC50 for 72 h exposure) for (a) 24, (b) 48,
and (c) 72 h and then stained with propidium iodide. Panels A1, B1, and C1 are untreated control groups. Panels A2, B2, and C2 are cells
treated with Pd@W.tea-NPs. (d) Qualitative data of flow cytometer. Values are mean± SD for three different independent experiments.
∗P< 0.05 by one-way ANOVA followed by Tukey’s B-test.
Table 1: Serum liver and renal function parameters of healthy (negative) control mice or with induced leukemia after 28 days of treatment as
stated.
Animal group ALP (U/L) ALT (U/L) AST (U/L) Urea (mmol/L) Creatinine (μmol/L)
Negative control 110.3± 2.1 60.9± 1.2 142.1.2± 1.3 7.85± 0.6 31.65± 0.8
Induced leukemia control 200.1± 1.1∗ 155.55± 1.5∗ 205.0.6± 0.9∗ 12.55± 0.5∗ 50.7± 2.3∗
Blank-NPs 195.01± 1.4∗ 149.2± 1.1∗ 197.5± 1.6∗ 11.95± 0.55∗ 51.6± 1.3∗
50mg/kg Pd@W.tea-NPs 151.0± 0.6Ψ 100.3± 1.7Ψ 175.1.8± 0.8Ψ 9.05± 0.65Ψ 39.4± 0.4Ψ
100mg/kg Pd@W.tea-NPs 128.4± 0.11Ψ 75.95± 1.45Ψ 155.1± 2.2Ψ 8.6.45± 0.25Ψ 35.23± 0.7Ψ
5mg/kg ATRA 112.3± 1.5Ψ 62.0± 1.0Ψ 146.2± 0.35Ψ 8.1± 0.5Ψ 32± 0.9Ψ
∗P< 0.05 compared with negative control, ΨP< 0.05 compared with induced leukemia control by one-way ANOVA followed by Tukey’s B-test. ALP: alkaline
phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase. Values are mean± SD (n� 6).
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nanoparticles in simple one-step green process [6]. 'e
palladium nanoparticles generated (Pd@W.tea-NPs) were
spherical, 6–8 nm in size and contained flavonoids and other
phenols derived from the white tea extract. 'ese nano-
particles were shown to have 1-diphenyl-2-picrylhydrazyl
(DPPH), OH, and NO-scavenging properties in vivo using
the MOLT-4 human leukemic cell line.
'e current study aimed to explore if Pd@W.tea-NPs
were effective against leukemia in vivo, using a mouse model
of induced leukemia. Effects of Pd@W.tea-NPs that are
consistent with anticancer activity in the mouse WEHI-3B
leukemic cell line that we report complement our in vivo
observations. Specifically, we found that both IC50 values
and maximum reduction in cell viability for the action of
Pd@W.tea-NPs over 24–72 h on WEHI-3B cells were lower
than the equivalent values for normal mouse fibroblasts.'is
demonstrates a selectivity towards leukemic compared with
normal cells, which is required for therapeutic efficacy.
Notably, the IC50 values we measured (16.77, 10.25, and
7.55 μg/ml for exposure over 24, 24, and 72 h, respectively)
are similar to the values measured in human MOLT-4
leukemic cells (4.97, 6.25, and 7.14 μg/ml, respectively, for
exposure over the same time periods) [6]. 'is parity adds
some confidence to the assertion that the positive anticancer
effects we observed in the mouse model will translate to













Figure 4: H&E staining (×1000 magnification) of spleen from healthy, control BALB/c mice (a); mice with induced leukemia (b); mice with
induced leukemia treated with 50mg/kg Pd@W.tea-NPs (c); mice with induced leukemia treated with 100mg/kg Pd@W.tea-NPs (d); mice
with induced leukemia treated with 100mg/kg blank Pd-NPs (e); and mice with induced leukemia treated with ATRA (f). Black arrows
indicate examples of cells scored as morphologically normal. Yellow arrows indicate examples of cells scored as neoplastic.













Figure 5: Detection of the CD3 T-cell marker by immunohistochemistry (×1000 magnification) in spleen from healthy, control BALB/c
mice (a); mice with induced leukemia (b); mice with induced leukemia treated with 50mg/kg Pd@W.tea-NPs (c); mice with induced
leukemia treated with 100mg/kg Pd@W.tea-NPs; (d); mice with induced leukemia treated with 100mg/kg blank Pd-NPs (e); and mice with
induced leukemia treated with ATRA (f).
Table 3: Histopathological scoring of spleen in mice with induced leukemia, or in healthy (negative) control animals, after 28 days of
treatment as stated.
Animal group Leukemic cells % Nonleukemic cells % Score Indication
Negative control 0.0± 0.0 100.0± 0.0 0 Normal
Induced leukemia control 85.51± 1.4a 14.49± 0.7 4 Severe change
50mg/kg Pd@W.tea-NPs 19.65± 0.45b 80.35± 0.55 1 Mild change
100mg/kg Pd@W.tea-NPs 18.2± 0.25b 81.8± 0.15 1 Mild change
Blank-NPs 72.25± 2.1a 27.75± 1.5 4 Severe change
5mg/kg ATRA 13.50± 0.16b 86.50± 0.26 1 Mild change
Values are mean± SD, n� 4 sections. a - P< 0.05 compared with negative control; b–P< 0.05 compared with induced leukemia control by one-way ANOVA
followed by Tukey’s B-test. Sections were stained with H&E.
Evidence-Based Complementary and Alternative Medicine 11
confirmed, that white tea extract-derived compounds in-
corporated into Pd@W.tea-NPs during their synthesis
would confer cytotoxic effects towards cancer cells that are
enhanced compared with “blank” Pd nanoparticles, gener-
ated in the absence of white tea extract. We previously
demonstrated that polyphenolic constituents of white tea are
incorporated into the Pd@W.tea-NPs6 and proposed these
to be the most likely candidates.
Defects in the normal cell cycle arrest response to DNA
damage may lead to development of cancer [23, 24], and
induction of cell cycle arrest is an important element of the
anticancer action of many chemotherapeutic agents used
clinically. Control over the cell cycle has been proven as the
main event in the process of cell division. 'e cell cycle
regulators and check points such as G2/M checkpoint
specifically is a target for anticancer therapy. Preventing
entry into mitosis (M-phase) stimulates the induction of
apoptotic pathways [24]. Our finding that Pd@W.tea-NPs,
but not blank nanoparticles, induced G2/M phase arrest
suggests that this action underlies, or at least contributes to,
the measured effects on WEHI-3B cell viability.
Macroscopic and cellular features of the spleen observed
in the mouse model of induced leukemia we used confirmed
the presence of characteristic features of the disease that
were ameliorated by Pd@W.tea-NPs administered orally at 2
different doses as well as by the anticancer drug ATRA,
which is a common, effective therapeutic agent used to treat













Figure 6: Detection of the CD19 B-cell marker by immunohistochemistry (×1000 magnification) in spleen from healthy, control BALB/c
mice (a); mice with induced leukemia (b); mice with induced leukemia treated with 50mg/kg Pd@W.tea-NPs (c); mice with induced
leukemia treated with 100mg/kg Pd@W.tea-NPs (d); mice with induced leukemia treated with 100mg/kg blank Pd-NPs (e); and mice with
induced leukemia treated with ATRA (f). Cells positive for CD19 are stained brown. Cells negative for CD3 are blue.
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weight of the spleen, most likely caused by the infiltration of
leukemic cells [25–27], is one such feature of the disease.'e
observed accumulation of cells with abnormal morphology,
characteristic of neoplastic cells, we observed in the diseased
mouse spleen, and the increased abundance of cells positive
for both the T-cell marker CD317 and the B-cell marker
CD1918, which are potential indicators for disease severity
[25], all point towards there being infiltration of leukemic
cells, hence replicating this feature of the human disease.
'is validation of the experimental model adds strength to
the argument that Pd@W.tea-NPs offer early promise as a
potential treatment for human leukemia.
Blank Pd nanoparticles were not efficacious against these
features of the disease demonstrating that, consistent with
the effects measured in vitro, the content of the nanoparticles
derived from the white tea extract provided efficacy. We did
not test white tea extract alone in the animal model since the









































Figure 7: Expression of Bcl-2, Bax, cytochrome-C, and GAPDH (loading control) detected by western blotting in spleen from healthy,
control BALB/cmice (A); mice with induced leukemia (B); mice with induced leukemia treated with 100mg/kg blank Pd-NPs (C); mice with
induced leukemia treated with 50mg/kg Pd@W.tea-NPs (D); mice with induced leukemia treated with 100mg/kg Pd@W.tea-NPs (E); and
mice with induced leukemia treated with 5mg/kg ATRA (F). 'e data shown are representative of multiple blots. Abbreviations: Cyt-C,
cytochrome-C; GAPHD, glyceraldehyde 3-phosphate dehydrogenase. Protein abundance was measured by densitometry using ImageJ 148-
JDK 6 software for n� 3 mice per group, each measured in triplicate. ∗P< 0.05 and ∗∗P< 0.05 by one-way ANOVA followed by Tukey’s B-
test. Values are mean± SD relative to GAPDH (loading control).
Table 4: Bcl-2, Bax, and cytochrome-C mRNA measured and normalized by GAPDH gene by RT-qPCR in spleen from healthy (negative)
control mice or mice with induced leukemia after 28 days of treatment as stated.
mRNA Control Leukemia Blank NPs (100mg/kg) Pd@W.tea-NPs (50mg/kg) Pd@W.tea-NPs (100mg/kg) ATRA (5mg/kg)
Bcl-2 12.5± 0.11 33.01± 1.15 31.23± 0.75 25.25± 0.25∗ 21.12± 0.44∗ 16.98± 1.1∗
Bax 14.07± 1.7 11.34± 1.0 11.55± 0.35 25.24± 0.20∗∗ 31.10± 0.17∗∗ 42.10± 2.2∗∗
Cyt-C 12.0± 1.15 8.60± 0.75 9.25± 0.25 21.54± 0.30∗∗ 26.45± 0.05∗∗ 34.05± 2.1∗∗
Values are mean± SD relative to GAPDH (loading control) measured by densitometry using ImageJ 148-JDK 6 software for n� 3 mice per group, each
measured in triplicate. ∗P< 0.05 and ∗∗P< 0.05 by one-way ANOVA followed by Tukey’s B-test.
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the effects of Pd@W.tea-NPs over the same concentration
range and on a par with the effects of the blank nano-
particles. 'us, in line with the principles of 3R, it was
considered better experimental design to exclude this test.
Since we observed effects of Pd@W.tea-NPs on the cell
cycle in WHEI-3B cells that can lead to the induction of
apoptosis, we posited that induction of apoptosis of leu-
kemic cells in the spleen contributed to the effect of Pd@
W.tea-NPs to reduce the size of the diseased spleen [28]. In
apoptosis, Bcl-2 and Bax proteins activates the cascade of
reactions by releasing cytochrome-C from the mitochondria
which in turn forms apoptosome that helps in consecutive
activation of caspases and eventually leads to cell death [29].
Particularly, in leukemia, Bcl-2/Bax ratio is an important
determinant of cell survival [30]. 'ese cytoplasmic proteins
are also involved in retiring proliferating cells back to G0
phase of the cell cycle [31]. 'e increased Bcl-2/Bax ratio we
observed in the spleen of the groups treated with Pd@W.tea-
NPs and the increased level of cleaved cytochrome-C, in-
dicating activation of the mitochondrial, caspase-induced
pathway of apoptosis, is consistent with this assertion and
replicated effects of ATRA we observed. In contrast, and
commensurate with our other negative observations, blank
nanoparticles did not induce these changes. 'e fact that
Pd@W.tea-NPs replicated actions of ATRA, a current
standard and effective treatment for leukemia, adds further
weight to the argument that these NPs merit further in-
vestigation as future agents for leukemia treatment.
Alongside progression of work in vivo towards con-
ducting clinical trials in patients, it would be worthwhile
conducting further research in vitro to gain more knowledge
of the delivery pathway of NP-delivered white tree extract
components into the intracellular milieu. Specifically, re-
solving the question of whether NPs enter the cell and
deliver their therapeutic cargo in soluble form to the cytosol,
if active components are released at the cell membrane
before entry into cells or if intracellular NPs per se are
bioactive could guide formula optimisation.
5. Conclusions
In the current research, we have demonstrated in vitro and in
vivo data on actions of Pd@W.tea-NPs that are consistent
and that reveal actions likely to afford therapeutic efficacy
against leukemia and likely to pivot on activation of the
mitochondrial, caspase-induced pathway of apoptotic sig-
naling. In all tests, Pd-NPs prepared in the absence of white
tea extract lacked these actions, which demonstrates that
components of the extract incorporated into the nano-
particles, likely to be polyphenolic compounds, contribute
these actions. 'us, Pd@W.tea-NPs are promising candi-
dates for leukemia therapy that merit further study in this
specific context and also as possible agents for the treatment
of other forms of cancer.
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